Clinical Trials Logo
  1. Home
  2. Biliary Tract Carcinoma
  3. NCT02105350

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

Biliary Tract Carcinoma Clinical Trial

Official title:
A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer

Clinical Trial Summary

This is a phase I study (an early study to check the safety of a new drug or drug combination) to find the safest and most tolerated dose of the combination of oxaliplatin with gemcitabine and MEK 162 in patients with biliary cancer (including gallbladder cancers and cancers associated with the bile ducts leading from the gallbladder and to and from the liver) that is not curable by surgery and/or has spread beyond the biliary tree (place where cancer started). Everyone will receive the same standard doses of oxaliplatin and gemcitabine but may receive different doses of MEK 162.

MEK 162 is a new drug which plays an important role in the regulation of cell growth and has been shown to shrink tumours in patients with biliary cancer and other types of human cancers. This type of drug has also been shown to shrink tumours when given in combination with cisplatin and gemcitabine in research studies done in animals and in some patients with biliary cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02105350
Study type Interventional
Source University Health Network, Toronto
Contact
Status Withdrawn
Phase Phase 1
Start date June 2015
Completion date June 2015
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05009953 - Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer Phase 2
Recruiting NCT05285358 - Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases Phase 1
Recruiting NCT04430738 - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Phase 1/Phase 2
Active, not recruiting NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1
Active, not recruiting NCT05222854 - Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"
Not yet recruiting NCT05681949 - Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards N/A
Active, not recruiting NCT02151084 - A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer Phase 2
Terminated NCT01855724 - Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Phase 2
Recruiting NCT04183712 - Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA Phase 2
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Completed NCT02649712 - Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction N/A
Recruiting NCT05194072 - A Study of SGN-B7H4V in Advanced Solid Tumors Phase 1
Recruiting NCT03581435 - A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients
Completed NCT03201458 - Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Phase 2
Completed NCT04740164 - A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP N/A
Completed NCT02333188 - Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Phase 1
Recruiting NCT05712356 - A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors Phase 2
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Recruiting NCT03702491 - Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma Phase 2
Recruiting NCT04068194 - Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Phase 1/Phase 2